Comparative Pharmacology
Head-to-head clinical analysis: ALLEGRA HIVES versus DRIXORAL PLUS.
Peer-Reviewed Evidence
Head-to-head clinical analysis: ALLEGRA HIVES versus DRIXORAL PLUS.
ALLEGRA HIVES vs DRIXORAL PLUS
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Fexofenadine is a non-sedating antihistamine (H1-receptor antagonist) that selectively inhibits peripheral H1 receptors, reducing histamine-mediated symptoms such as pruritus, urticaria, and vasodilation. It does not cross the blood-brain barrier significantly, minimizing CNS effects.
DRIXORAL PLUS contains dexbrompheniramine, an antihistamine that competes with histamine for H1-receptor sites, suppressing histamine-induced symptoms; and pseudoephedrine, a sympathomimetic amine that directly acts on alpha-adrenergic receptors in the respiratory tract mucosa, causing vasoconstriction and reducing nasal congestion.
Fexofenadine hydrochloride 60 mg orally twice daily or 180 mg orally once daily.
1 tablet orally every 12 hours, not to exceed 2 tablets in 24 hours.
None Documented
None Documented
Terminal elimination half-life is approximately 14.4 hours (range 11–17 hours). This supports once-daily dosing in most patients; however, in moderate to severe renal impairment, half-life may be prolonged (e.g., ~22 hours), necessitating dosing adjustment.
Pseudoephedrine: ~9-16 hours (pH-dependent, longer in alkaline urine). Dexbrompheniramine: ~20-25 hours. Clinical context: multiple dosing accumulates.
Fexofenadine is primarily excreted unchanged in feces (80%) and urine (11%). The remainder undergoes minimal hepatic metabolism. Renal elimination accounts for about 11% of the dose.
Renal: 50-70% unchanged for pseudoephedrine; hepatic metabolism for dexbrompheniramine with renal excretion of metabolites.
Category C
Category C
Antihistamine
Antihistamine/Decongestant